[轴细胞CAR-T治疗老年晚期双表达DLBCL患者一线化疗免疫治疗难治性的经验]

Q3 Medicine

Recenti progressi in medicina Pub Date : 2025-02-01 DOI:10.1701/4450.44451

Maria Goldaniga

{"title":"[轴细胞CAR-T治疗老年晚期双表达DLBCL患者一线化疗免疫治疗难治性的经验]","authors":"Maria Goldaniga","doi":"10.1701/4450.44451","DOIUrl":null,"url":null,"abstract":"We hereby describe a case of successful therapy with axicabtagene ciloleucel (axi-cel) chimeric antigen receptor T-cells (CAR-T) in an elderly patient suffering from DLBCL refractory to first-line chemoimmunotherapy, with particular reference to the setting of the diagnostic/therapeutic path and collaboration between the Referral center and the CAR-T center.","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"116 2","pages":"e28-e32"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Experience of therapy with axi-cel CAR-T in an elderly patient suffering from double expressor DLBCL in an advanced stage and refractory to first-line chemoimmunotherapy.]\",\"authors\":\"Maria Goldaniga\",\"doi\":\"10.1701/4450.44451\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We hereby describe a case of successful therapy with axicabtagene ciloleucel (axi-cel) chimeric antigen receptor T-cells (CAR-T) in an elderly patient suffering from DLBCL refractory to first-line chemoimmunotherapy, with particular reference to the setting of the diagnostic/therapeutic path and collaboration between the Referral center and the CAR-T center.\",\"PeriodicalId\":20887,\"journal\":{\"name\":\"Recenti progressi in medicina\",\"volume\":\"116 2\",\"pages\":\"e28-e32\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Recenti progressi in medicina\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1701/4450.44451\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recenti progressi in medicina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1701/4450.44451","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

我们在此描述一个用axicabtagene ciloleucel（轴细胞）嵌合抗原受体t细胞（CAR-T）成功治疗一线化疗免疫治疗难治的老年DLBCL患者的病例，特别提到了诊断/治疗路径的设置以及转诊中心和CAR-T中心之间的合作。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

[Experience of therapy with axi-cel CAR-T in an elderly patient suffering from double expressor DLBCL in an advanced stage and refractory to first-line chemoimmunotherapy.]

We hereby describe a case of successful therapy with axicabtagene ciloleucel (axi-cel) chimeric antigen receptor T-cells (CAR-T) in an elderly patient suffering from DLBCL refractory to first-line chemoimmunotherapy, with particular reference to the setting of the diagnostic/therapeutic path and collaboration between the Referral center and the CAR-T center.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Recenti progressi in medicina Medicine-Medicine (all)

CiteScore

0.90

自引率

0.00%

发文量

143

期刊介绍： Giunta ormai al sessantesimo anno, Recenti Progressi in Medicina continua a costituire un sicuro punto di riferimento ed uno strumento di lavoro fondamentale per l"ampliamento dell"orizzonte culturale del medico italiano. Recenti Progressi in Medicina è una rivista di medicina interna. Ciò significa il recupero di un"ottica globale e integrata, idonea ad evitare sia i particolarismi della informazione specialistica sia la frammentazione di quella generalista.